High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response is a paper indexed in ScholarIQ from OpenAlex.
How many citations does High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response have?
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response has 1,450 citations in the OpenAlex counts ScholarIQ stores.
When was High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response published?
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response has 2015 year in the ScholarIQ index.
What is the open-access status of High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response?
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response has closed oa status in the ScholarIQ index.
What is the DOI of High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response?
The DOI for High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response is on the source record.
What is the PMID of High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response?
The PMID for High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response is on the source record.
What is the OpenAlex record for High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response?
The OpenAlex for High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response is on the source record.